Compound research
Epithalon: Research Overview & Current Status
Epithalon is a Synthetic tetrapeptide (pineal gland-derived research peptide). Current research status: preclinical research. Epithalon has no FDA or EMA approval. Human evidence is limited largely to older cohort/observational data on the related compound epithalamin (a distinct pineal extract, not the synthetic tetrapeptide) plus small non-Western clinical reports; robust, modern, independently replicated human trials of synthetic Epithalon specifically are lacking.
Overview
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from research into epithalamin, a bovine pineal gland extract studied in Russian gerontology research led by Vladimir Khavinson. It is investigated primarily for effects on telomerase activity and cellular senescence markers.
Synthetic tetrapeptide (pineal gland-derived research peptide)
Research timeline
2003
Foundational in vitro study reported that Epithalon induced telomerase activity and telomere elongation in human somatic cells.
Source →2004
Follow-up study reported Epithalon allowed human fetal fibroblasts to exceed their normal Hayflick division limit by at least 10 additional divisions versus controls.
Source →2000s
Animal studies reported lifespan extension in flies and rats and reduced age-related chromosomal abnormalities in mice following Epitalon administration.
Source →2000s-2010s
Cohort/observational studies on the related compound epithalamin (pineal extract, distinct from synthetic Epithalon) reported associations with improved physiological markers in older populations across multi-year follow-up.
Source →2025
Cell-line study examined Epitalon in normal epithelial cells, fibroblasts, and breast cancer cell lines, reporting dose-dependent telomere elongation in normal cells via hTERT/telomerase upregulation, while cancer cells showed a different response pattern.
Source →
Active & recent research
Epitalon effects on telomerase and telomere length across normal vs. cancer cell lines
Comparing dose-dependent telomere elongation mechanisms (hTERT/telomerase upregulation vs. alternative lengthening) between normal and malignant cells
Pineal peptide preparations and geroprotection
Synthesizing decades of pineal-extract and synthetic-tetrapeptide research on aging biomarkers
Key findings
- A 2003 in vitro study reported that Epithalon induced telomerase activity and telomere elongation in human somatic cells — the foundational finding underpinning most subsequent interest in the peptide.
- A 2025 cell-line study reported dose-dependent telomere length extension in normal cells (via apparent hTERT/telomerase upregulation) but noted cancer cell lines appeared to rely on different, alternative telomere-lengthening mechanisms — an important distinction researchers flag for safety interpretation.
- Animal studies have reported lifespan extension in flies and rats, but these findings have not been confirmed in controlled human lifespan or healthspan trials.
- Reviews caution that human data are dominated by older, non-Western observational cohorts on a related pineal extract (epithalamin) rather than rigorous modern RCTs of the synthetic tetrapeptide itself, and that the two compounds should not be conflated.
Safety & regulatory notes
Epithalon is not FDA-approved and has no established human dosing or long-term safety data from controlled trials. Reviews explicitly flag that non-approved peptides like Epitalon lack long-term safety data and systematic clinical validation. Because telomerase activation is mechanistically linked to processes relevant to cancer biology, researchers highlight this as an area requiring careful further study rather than an established risk or benefit.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for Epithalon yet. See our full research-peptide vendor rankings →
Epithalon FAQ
Has Epithalon been tested in human clinical trials?+
Robust, modern, independently replicated human clinical trials of the synthetic Epithalon tetrapeptide are lacking; most human-adjacent data come from older observational cohorts studying a related but distinct pineal extract (epithalamin).
What is the evidence for Epithalon and telomeres?+
The evidence is strongest at the cell-culture level, where a 2003 study and later work reported telomerase induction and telomere elongation in human somatic cells, supported by some animal lifespan data — but this has not been established in controlled human trials.
Is Epithalon approved by the FDA?+
No. Epithalon has no FDA or EMA approval for any indication and remains an investigational research compound.
Are Epithalon and epithalamin the same thing?+
No — epithalamin is a bovine pineal gland extract studied in earlier Russian research, while Epithalon (Epitalon) is a synthetic tetrapeptide developed based on its amino acid composition; sources caution against conflating findings between the two.
Sources for this page (5)
- 1 https://pubmed.ncbi.nlm.nih.gov/12937682/
- 2 https://www.researchgate.net/publication/10598271_Epithalon_Peptide_Induces_Telomerase_Activity_and_Telomere_Elongation_in_Human_Somatic_Cells
- 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943447/
- 4 https://www.gethealthspan.com/research/article/epitalon
- 5 https://meto.co/blog/epitalon-telomeres-aging-peptide
Related: all compound research overviews · research radar · full vendor rankings · methodology